Study Conduct

Profil Institute, LMC Diabetes partnership on cross-border multi-site trials

Wednesday, June 15, 2016

Profil Institute for Clinical Research, a science-driven CRO focused exclusively on metabolic diseases, and LMC Diabetes & Endocrinology, North America’s largest network of investigator sites for diabetes clinical research, have announced a strategic alliance focused on the conduct of cross-border, multi-site clinical research of investigational drugs and devices for diabetes and related metabolic disorders.

[Read More]

Three Questions: Jim Murphy, Greenphire

Monday, June 13, 2016

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Suz Redfearn spoke with Jim Murphy, CEO of Greenphire, which offers global clinical trial payment solu­tions.

[Read More]

Survey: SCORR to present industry thoughts on Big Data, recruitment, confidentiality

Friday, June 10, 2016

SCORR Marketing, a global health science marketing and communications firm, and Chesapeake IRB, a technology-enabled independent institutional review board (IRB) serving the clinical research industry, will present “Does ‘Big Data’ for Enhanced Recruiting Invade Patient Confidentiality?” and “The Internet of Things and Clinical Research: Privacy, Security and Ethical Aspects” at the Drug Information Association (DIA) Annual Meeting in Philadelphia.

[Read More]

Biologics Consulting launches Clinical Trials Planning and Oversight Group

Wednesday, June 8, 2016

Biologics Consulting, a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices, has launched its Clinical Trials Planning and Oversight Group. The group will help small and medium-sized biopharmaceutical companies in the development and management of efficient and cost effective clinical trials. Biologics Consulting has a broad range of global clinical trial experience and clinical operations expertise that it will leverage to help clients design trials to meet the ethical, regulatory and scientific standards required to obtain successful product development outcomes.

[Read More]

IMS Health acquires Privacy Analytics

Monday, June 6, 2016

IMS Health has acquired Privacy Analytics, a provider of technology solutions for de-identifying and anonymizing healthcare information, to extend its Real-World Evidence (RWE) capabilities. Affirming IMS Health’s long-standing practices for safeguarding patient privacy, the acquisition advances the company’s ability to help life sciences clients drive R&D and commercial performance and demonstrate treatment value in real-world settings. It also reinforces IMS Health’s role as a partner of choice for health systems, payers, providers and researchers as they seek new insights from healthcare data—with strong support for responsible privacy management.

[Read More]